Exelixis price target raised to $29 vs. $25 at Oppenheimer
Oppenheimer has raised its Exelixis Inc. (EXEL) price target to $29 from $25, citing the biotech's Phase 3 CONTACT-02 trial evaluating Cabozantinib in combination with Atezolizumab. "We believe positive Ph3 CONTACT-02 topline results for cabo+atezo in mCRPC [metastatic castration-resistant prostate cancer] should support potential regulatory discussions for the first potential non-cytotoxic and non-chemo therapy in this setting, which we see as a meaningful opportunity based on the current prognosis of 2 years," wrote Oppenheimer analyst Jay Olson, in a note. "CONTACT-02 met one of two primary endpoints by demonstrating a significant improvement in PFS [progression-free survival] while a trend in OS [overall survival] improvement was observed although data were immature at this first analysis." Exelixis stock is up 0.61% in premarket trades Tuesday after ending Monday's session up 1.3%.
-James Rogers
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-22-23 0919ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom